Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Elevation Oncology Inc (NASDAQ: ELEV) closed at $3.62 down -0.69% from its previous closing price of $3.64. In other words, the price has decreased by -$0.69 from its previous closing price. On the day, 0.87 million shares were traded. ELEV stock price reached its highest trading level at $3.83 during the session, while it also had its lowest trading level at $3.5799.
Ratios:
For a deeper understanding of Elevation Oncology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.22 and its Current Ratio is at 21.22. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.55.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on March 01, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $7.
On May 30, 2023, SVB Securities Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $5 to $8.
On December 23, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $12.H.C. Wainwright initiated its Buy rating on December 23, 2021, with a $12 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELEV now has a Market Capitalization of 176116976 and an Enterprise Value of 123147040.
Stock Price History:
The Beta on a monthly basis for ELEV is 1.52, which has changed by 0.18300653 over the last 52 weeks, in comparison to a change of 0.22363698 over the same period for the S&P500. Over the past 52 weeks, ELEV has reached a high of $5.89, while it has fallen to a 52-week low of $0.36. The 50-Day Moving Average of the stock is -14.14%, while the 200-Day Moving Average is calculated to be 95.11%.
Shares Statistics:
For the past three months, ELEV has traded an average of 1.19M shares per day and 679250 over the past ten days. A total of 42.42M shares are outstanding, with a floating share count of 37.99M. Insiders hold about 21.92% of the company’s shares, while institutions hold 66.24% stake in the company. Shares short for ELEV as of 1713139200 were 4951682 with a Short Ratio of 4.17, compared to 1710460800 on 4625273. Therefore, it implies a Short% of Shares Outstanding of 4951682 and a Short% of Float of 11.3199994.
Earnings Estimates
The current rating of Elevation Oncology Inc (ELEV) reflects the combined expertise of 5.0 analysts actively engaged in assessing its market performance.On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.23, while EPS last year was -$0.72. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.18 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.76 and -$0.92 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.89, with 5.0 analysts recommending between -$0.62 and -$1.3.
